A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Clinical trial NCT03625141 · COMPLETED

Trial details

NCT number: NCT03625141
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Melanoma

Start date: 2018-12-13
Primary completion: 2021-06-07
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.